Literature DB >> 21098684

Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index.

Elizabeth A Lawson1, Kamryn T Eddy, Daniel Donoho, Madhusmita Misra, Karen K Miller, Erinne Meenaghan, Janet Lydecker, David Herzog, Anne Klibanski.   

Abstract

OBJECTIVE: Disordered eating occurs in women at both weight extremes of anorexia nervosa (AN) and obesity. Cortisol, peptide YY (PYY), leptin, and ghrelin are hormones involved in appetite and feeding behavior that vary with weight and body fat. Abnormal levels of these hormones have been reported in women with AN, functional hypothalamic amenorrhea (HA), and obesity. The relationship between appetite-regulating hormones and disordered eating psychopathology is unknown. We therefore studied the relationship between orexigenic and anorexigenic hormones and disordered eating psychopathology in women across a range of weights.
DESIGN: A cross-sectional study of 65 women, 18-45 years: 16 with AN, 12 normal-weight with HA, 17 overweight or obese, and 20 normal-weight in good health.
METHODS: Two validated measures of disordered eating psychopathology, the Eating Disorders Examination-Questionnaire (EDE-Q) and Eating Disorders Inventory-2 (EDI-2), were administered. Fasting PYY, leptin, and ghrelin levels were measured; cortisol levels were pooled from serum samples obtained every 20 min from 2000 to 0800 h.
RESULTS: Cortisol and PYY levels were positively associated with disordered eating psychopathology including restraint, eating concerns, and body image disturbance, independent of body mass index (BMI). Although leptin levels were negatively associated with disordered eating psychopathology, these relationships were not significant after controlling for BMI. Ghrelin levels were generally not associated with EDE-Q or EDI-2 scores.
CONCLUSIONS: Higher levels of cortisol and PYY are associated with disordered eating psychopathology independent of BMI in women across the weight spectrum, suggesting that abnormalities in appetite regulation may be associated with specific eating disorder pathologies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098684      PMCID: PMC3677777          DOI: 10.1530/EJE-10-0523

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  47 in total

1.  Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples.

Authors:  Hiroshi Hosoda; Kentaro Doi; Noritoshi Nagaya; Hiroyuki Okumura; Eiichiro Nakagawa; Mitsunobu Enomoto; Fumiaki Ono; Kenji Kangawa
Journal:  Clin Chem       Date:  2004-06       Impact factor: 8.327

2.  Disordered eating cognitions and behaviours among slimming organization competition winners.

Authors:  G C Green; J Buckroyd
Journal:  J Hum Nutr Diet       Date:  2008-02       Impact factor: 3.089

3.  Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion.

Authors:  Tomomi Shiiya; Masamitsu Nakazato; Masanari Mizuta; Yukari Date; Muhtashan S Mondal; Muneki Tanaka; Shin-Ichi Nozoe; Hiroshi Hosoda; Kenji Kangawa; Shigeru Matsukura
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

4.  Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea.

Authors:  B M Biller; H J Federoff; J I Koenig; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1990-02       Impact factor: 5.958

5.  Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa.

Authors:  Elizabeth A Lawson; Daniel Donoho; Karen K Miller; Madhusmita Misra; Erinne Meenaghan; Janet Lydecker; Tamara Wexler; David B Herzog; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

6.  Hypothalamic-pituitary-adrenal (HPA) axis functioning in relation to body fat distribution.

Authors:  Femke Rutters; Arie G Nieuwenhuizen; Sofie G T Lemmens; Jurriaan M Born; Margriet S Westerterp-Plantenga
Journal:  Clin Endocrinol (Oxf)       Date:  2009-09-21       Impact factor: 3.478

7.  The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight loss.

Authors:  Ira C Packianathan; Maleyca Sheikh; Sarah Feben; Nick Finer
Journal:  Eat Behav       Date:  2002

8.  Leptin and its associations with measures of psychopathology in patients with anorexia nervosa.

Authors:  Stefan Ehrlich; Roland Burghardt; Nora Schneider; Jakob Hein; Deike Weiss; Ernst Pfeiffer; Ulrike Lehmkuhl; Harriet Salbach-Andrae
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

9.  Inhibition of food intake in obese subjects by peptide YY3-36.

Authors:  Rachel L Batterham; Mark A Cohen; Sandra M Ellis; Carel W Le Roux; Dominic J Withers; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

10.  Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake.

Authors:  K K Miller; M S Parulekar; E Schoenfeld; E Anderson; J Hubbard; A Klibanski; S K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  34 in total

Review 1.  Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin.

Authors:  Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye
Journal:  Mol Cell Endocrinol       Date:  2018-11-02       Impact factor: 4.102

2.  Cortisol Measures Across the Weight Spectrum.

Authors:  Melanie Schorr; Elizabeth A Lawson; Laura E Dichtel; Anne Klibanski; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

Review 3.  The endocrine manifestations of anorexia nervosa: mechanisms and management.

Authors:  Melanie Schorr; Karen K Miller
Journal:  Nat Rev Endocrinol       Date:  2016-11-04       Impact factor: 43.330

4.  Low Fasting Oxytocin Levels Are Associated With Psychopathology in Anorexia Nervosa in Partial Recovery.

Authors:  Yuliya Afinogenova; Cindy Schmelkin; Franziska Plessow; Jennifer J Thomas; Reitumetse Pulumo; Nadia Micali; Karen K Miller; Kamryn T Eddy; Elizabeth A Lawson
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

Review 5.  Endocrine effects of anorexia nervosa.

Authors:  Karen Klahr Miller
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

Review 6.  Endocrine consequences of anorexia nervosa.

Authors:  Madhusmita Misra; Anne Klibanski
Journal:  Lancet Diabetes Endocrinol       Date:  2014-04-02       Impact factor: 32.069

7.  Leptin secretory dynamics and associated disordered eating psychopathology across the weight spectrum.

Authors:  Charumathi Baskaran; Kamryn T Eddy; Karen K Miller; Erinne Meenaghan; Madhusmita Misra; Elizabeth A Lawson
Journal:  Eur J Endocrinol       Date:  2016-04       Impact factor: 6.664

8.  Bone density, body composition, and psychopathology of anorexia nervosa spectrum disorders in DSM-IV vs DSM-5.

Authors:  Melanie Schorr; Jennifer J Thomas; Kamryn T Eddy; Laura E Dichtel; Elizabeth A Lawson; Erinne Meenaghan; Margaret Lederfine Paskal; Pouneh K Fazeli; Alexander T Faje; Madhusmita Misra; Anne Klibanski; Karen K Miller
Journal:  Int J Eat Disord       Date:  2016-08-16       Impact factor: 4.861

9.  Anorexia induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY.

Authors:  Brenna M Flannery; Erica S Clark; James J Pestka
Journal:  Toxicol Sci       Date:  2012-08-17       Impact factor: 4.849

10.  Appetite regulatory hormones in women with anorexia nervosa: binge-eating/purging versus restricting type.

Authors:  Kamryn T Eddy; Elizabeth A Lawson; Christina Meade; Erinne Meenaghan; Sarah E Horton; Madhusmita Misra; Anne Klibanski; Karen K Miller
Journal:  J Clin Psychiatry       Date:  2015-01       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.